News & Events
Oxygen Biotherapeutics Secures Long-Term Clinical Supply of Oxycyte®
Company on Track to Resume Phase IIb Traumatic Brain Injury Trial Later This Year
MORRISVILLE, N.C., May 3, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT), a development stage biomedical company ("the Company") focused on developing perfluorocarbon-based intravenous and topical drug candidates, today announced it has achieved the critical milestone of securing an exclusive supply of cGMP-compliant Oxycyte®, the Company's proprietary perfluorocarbon based emulsion, that will take the Company through the current Phase II clinical trial for traumatic brain injury (TBI) and well into Phase III trials.
Key to this recent development was the signing of a contract with the manufacturer of cGMP-compliant FtBu, the proprietary, patent-protected active pharmaceutical ingredient in Oxycyte. Per the agreement, Oxygen Biotherapeutics has the exclusive rights to the supply of FtBu manufactured by this supplier. In addition, the Company is now aligned with a California-based contract manufacturer that will produce Oxycyte based on the Company's new scaled-up process for making the emulsion. Results from recent engineering batches made by this new supplier demonstrate that Oxycyte continues to meet all required specifications for product release. more..
Quick Links
Perfluorocarbon Emulsions as a Promising Technology: A Review of Tissue and Vascular Gas Dynamics
Journal of Applied Physiology
Perfluorocarbon Emulsions Improve Cognitive Recovery After Lateral Fluid Percussion Brain Injury In Rats
Neurosurgery
Reduction of hypoxia by perfluorocarbon emulsion in a traumatic spinal cord injury model
J. Neurosurg.: Spine
Perfluorocarbon Emulsion does not Impact Coagulation and Platelet Function in vitro
Poster Presentation
Safety and efficacy of Early Administration of the Perfluorocarbon OXYCYTE to Improve Cerebral Oxygenation after Severe Traumatic Brain Injury
Poster Presentation